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Abstract
Background: The emergence of antibiotic resistant bacteria in recent decades has highlighted the importance of
developing new drugs to treat infections. However, in addition to the design of new drugs, the development of accurate
preclinical testing methods is essential. In vivo imaging technologies such as bioluminescence imaging (BLI) or magnetic
resonance imaging (MRI) are promising approaches. In a previous study, we showed the effectiveness of 19F MRI using
perfluorocarbon (PFC) emulsions for detecting the site of Staphylococcus aureus infection. In the present follow-up study, we
investigated the use of this method for in vivo visualization of the effects of antibiotic therapy.
Methods/Principal findings: Mice were infected with S. aureus Xen29 and treated with 0.9% NaCl solution, vancomycin or
linezolid. Mock treatment led to the highest bioluminescence values during infection followed by vancomycin treatment.
Counting the number of colony-forming units (cfu) at 7 days post-infection (p.i.) showed the highest bacterial burden for
the mock group and the lowest for the linezolid group. Administration of PFCs at day 2 p.i. led to the accumulation of 19F at
the rim of the abscess in all mice (in the shape of a hollow sphere), and antibiotic treatment decreased the 19F signal
intensity and volume. Linezolid showed the strongest effect. The BLI, cfu, and MRI results were comparable.
Conclusions: 19F-MRI with PFCs is an effective non-invasive method for assessing the effects of antibiotic therapy in vivo.
This method does not depend on pathogen specific markers and can therefore be used to estimate the efficacy of
antibacterial therapy against a broad range of clinically relevant pathogens, and to localize sites of infection.
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Introduction
The emergence and spread of antibiotic resistant pathogens
such as methicillin-resistant Staphylococcus aureus (MRSA) has led to
a dramatic increase in the number of cases of invasive, life-
threatening infection and a high rate of treatment failure in recent
decades [1,2]. Furthermore, MRSA strains were limited to
hospital or clinical settings (hospital-acquired MRSA=ha-
MRSA); however, they are now widespread in the community
(community-associated MRSA=ca-MRSA) [3] and have even
affected livestock (livestock-associated MRSA= la-MRSA) [4].
The multi-resistance pattern of MRSA strains restricts treatment
options to a small subset of available antibiotics, and treatment
with these antibiotics might lead to the emergence of resistant
strains, resulting in an even more pronounced limitation of
treatment options [5]. Therefore, it is of paramount importance to
develop new promising drug candidates and lead compounds to
combat bacterial infections in the future. In addition, the
establishment of highly predictive in vivo models could help
accelerate the selection process and capture the whole spectrum of
activity of novel compounds in vivo. A promising approach to
facilitate the screening process is the application of in vivo imaging
technologies to preclinical testing [6,7]. Technologies such as
positron emission tomography, computed tomography, magnetic
resonance (MRI) or bioluminescence imaging (BLI) enable the
non-invasive visualization and quantification of disease progres-
sion in a longitudinal fashion [8]. These techniques may help limit
the need for animal testing, in addition to providing detailed
information about disease severity and complexity.
BLI is an effective method of visualizing the bacterial burden
during an infection and has provided detailed information about
the activity of antibiotics in several infectious disease models
[9,10]. However, one disadvantage of this technique is that it
requires the introduction of a light-emitting luciferase into the
pathogen of interest. This circumstance prohibits testing of new
compounds against not genetically modified strains and cannot be
easily transferred to the clinic, because pathogenic bacteria lack
luciferase. On the other hand, MRI does not require a gene-
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reporter or a fluorescent molecule to visualize differences between
infected and not-infected tissues. The use of MRI to assess the
effects of antibacterial therapy was examined in a S. aureus thigh
abscess model, in which changes in T2 relaxation times were
compared with those observed in a mock-treated group; however,
quantification and distinguishing between infected and not-
infected tissues was difficult [11].
19F MRI using perfluorocarbon (PFC) emulsions might
overcome this problem by enabling background-free visualization
of the administered contrast media using objective measurement
parameters [12,13]. Intravenous administration of a PFC emulsion
results in the accumulation of PFCs at the site of inflammation
because they are phagocytosed by immune cells in the blood,
which then migrate to inflammatory sites [14,15]. We recently
used a S. aureus thigh infection model to show that 19F MRI with
PFCs enables visualization of the site of infection. The PFC tracer
accumulates at the rim of the abscess in the shape of a hollow
sphere, thereby defining the infected area [16].
Therefore, the aim of the present study was to determine the
efficacy of 19F MRI for the non-invasive in vivo assessment of the
effects of antibacterial therapy. Mice were infected with S. aureus
and treated with two standard anti-MRSA antibiotics: vancomycin
and linezolid. Comparative analysis of the 19F accumulation
pattern, the bioluminescence signals generated by luciferase-
expressing S. aureus, and the number of colony-forming units (cfu)
showed that 19F-MRI with PFCs is an effective method for
visualizing and quantifying the effects of antibiotic therapy in vivo.
Results
Bioluminescence Imaging of the Response to
Antibacterial Therapy
The S. aureus strain, Xen29, which harbors a stable copy of the
Photorhabdus luminescens luxABCDE operon and therefore emits a
bioluminescent signal [9], was injected (at a dose of 3.26108 cfu)
into the left thigh muscle after a first control BL image was
obtained. The average radiance was quantified applying a
standardized oval area of interest to all measurements (Fig. 1A).
High photon emission was observed 15 min after the injection of
bacteria, but the signal decreased sharply until day 1 post-injection
(p.i.) in all groups. In the mock-treated group, the average
radiance increased and reached a plateau phase between day 3
and day 7 p.i. Treatment with either vancomycin or linezolid
resulted in a reduction in bioluminescence (beginning on day 2
p.i.), compared with that in the mock-treated group. The greatest
reduction was observed in response to linezolid treatment. The
mean average radiance on day 3 p.i. was 2.860.766104 p/s/cm2/
sr for the mock-treated group, 1.460.366104 p/s/cm2/sr for the
vancomycin group, and 2.1960.486103 p/s/cm2/sr for the
linezolid group (p,0.01 vs. 0.9% NaCl; p,0.05 vs. vancomycin).
On day 7 p.i., the mean average radiance values at the area of
interest for the mock, vancomycin, and linezolid groups were
4.7962.766104, 7.4062.026103 (p,0.05 vs. 0.9% NaCl group)
and 1.8560.156103 p/s/cm2/sr (p,0.01 vs. 0.9% NaCl; p,0.05
vs. vancomycin), respectively. These results indicate that, when
compared with the 0.9% NaCl-treated group, vancomycin
treatment reduced the bioluminescent signal by 49% on day 3
p.i., and by 85% on day 7 p.i. Linezolid led to a 92% reduction on
day 3 p.i. and a 96% reduction on day 7 p.i.
Bacterial Burden on Day 7 Post-infection
The muscles were harvested on day 7 p.i., homogenized, and
the number of colony-forming units was determined (Fig. 1B). The
mean cfu values in the infected thigh muscle were 6.5563.746109
for the mock-treated group, 2.561.976107 for the vancomycin-
treated group (2 log10 units lower than that in the mock control)
and 3.862.586103 for the linezolid-treated group (a 6 log10 unit
reduction).
Visualization of 19F at the Site of Infection during
Antibiotic Therapy
Circulating phagocytic cells incorporate intravenously-adminis-
tered PFC emulsions and migrate to the site of inflammation,
leading to the accumulation of the tracer at this site [14,17]. In the
S. aureus thigh abscess model, administration of PFC to the mock-
treated group resulted in the accumulation of the 19F tracer at the
rim of the abscess, which was consistent with the results of our
previous study [16]. Vancomycin treatment reduced the size of the
abscess, and linezolid had an even greater effect (Fig. 2).
Nevertheless, the pattern of 19F accumulation at the rim of the
abscess was, in terms of geometry, comparable in all three groups.
Estimation of 19F Accumulation at the Site of Infection
during Antibiotic Therapy
To estimate the volume of the abscess, we measured the
accumulation of the 19F tracer at the site of infection and
calculated the total volume of 19F-accumulation by adding all
‘fluorine filled’ voxels. The corresponding values are plotted in
Fig. 3. The highest 19F volumes were detected in the mock-treated
group on days 3 and 7 p.i. (3.4360.346104 and 4.0660.586104
voxels, respectively). The values in the vancomycin-treated group
were 5.9461.486103 and 8.2562.406103 voxels at days 3 and 7
p.i., respectively (p,0.01 vs. 0.9% NaCl at both time points). The
19F volumes in the linezolid-treated group were 2.7361.176103
and 2.6660.936103 voxels at days 3 and 7 p.i., respectively
(p,0.01 vs. 0.9% NaCl and p,0.05 vs. vancomycin at both time
points). These results indicate that, compared with the mock-
treated group, vancomycin reduced the 19F volume by 83% and
80%, and linezolid reduced the 19F volume by 92% and 93% at
days 3 and 7 p.i., respectively.
Because phagocytosis of the 19F tracer by immune cells leads to
its accumulation at the site of inflammation, the total 19F signal in
the abscess area can serve as a surrogate marker for the immune
response [14,17]. Therefore, we calculated the total 19F signal by
adding the signals of all individual 19F pixels over the entire
abscess area (Fig. 4). The value for the mock-treated group was
1.2960.226105 nsif (19F MR signal intensity normalized to the
apparent noise amplitude of the measurement) at day 3 and
1.9760.416105 nsif at day 7 p.i. In the vancomycin-treated
group, these values were 2.0360.676104 and 3.4161.376104 nsif
at days 3 and 7 p.i., respectively (p,0.01 vs. 0.9% NaCl at both
time points). The values for linezolid were 7.3163.646103 and
1.2160.466104 nsif at days 3 and 7 p.i., respectively (p,0.01 vs.
0.9% NaCl and p,0.05 vs. vancomycin at both time points).
These results show that the highest values for the 19F signal were
detected in the mock-treated group, and that vancomycin
treatment reduced the signal intensity by 84% and 83% at days
3 and 7 p.i., respectively, whereas the reduction induced by
linezolid was 94% and 96% at days 3 and 7 p.i., respectively.
Discussion
The present study investigated the use of 19F MRI using PFCs
as a tracer to visualize and evaluate responses to antibiotic therapy
in a preclinical infectious disease model. A non-invasive imaging
method for the in vivo screening of new drugs may provide
accurate and detailed information about disease progression and
minimize the use of experimental animals [6]. The recent
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development of BLI has enabled the imaging of bacterial infection
and the visualization and quantification of the effects of
antibacterial therapy in vivo [9,10]. Therefore, the present study
used BLI as a reference method for determining the efficacy of 19F
MRI using PFCs as platform for assessing the effects of antibiotics.
Figure 1. Effect of antibiotic therapy on bacterial burden in a thigh muscle abscess model. Bioluminescent S. aureus Xen29 (3.26108 cfu)
was injected into the left thigh muscle of mice, which were treated with either 0.9% NaCl (n = 6), vancomycin (n = 5), or linezolid (n = 5). A) Luciferase
expression in mice injected with S. aureus Xen 29 resulted in the emission of bioluminescence at the site of infection. Mean (6 SEM) bioluminescence
values are shown at the indicated time points. B) Infected thigh muscles were harvested on day 7 post-infection and the number of colony-forming
units was counted after homogenization and plating. The cfu values for each infected muscle, and the median number for each group, are shown.
Statistically significant differences between the groups are indicated by asterisks (**P,0.01).
doi:10.1371/journal.pone.0064440.g001
Figure 2. Representative 19F chemical shift imaging steady-state free precession overlays on 1H-turbo spin echo scans of one
mouse from each group during infection and antibiotic therapy. S. aureus Xen 29 (3.26108) was injected into the left thigh muscle and the
PFC tracer was administered intravenously 48 h post-infection. Each mouse underwent magnetic resonance imaging at 12 h and 120 h after PFC
administration. All groups showed strong accumulation of 19F at the rim of the abscess area. The 19F signal intensity is indicated by the hot (red to
white) color scale superimposed over a grey 1H image, which shows the anatomical context.
doi:10.1371/journal.pone.0064440.g002
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In our experimental model, animals were infected with S. aureus
Xen29, which was derived from strain NCTC8532 via the
insertion of the luxABCDE operon at a single chromosomal site [9],
to enable BLI during antibiotic treatment. The advantage of
in vivo BLI is that the same animal can be imaged at several time
points during the course of infection, thereby minimizing
individual variations in infected animals. Untreated control
animals showed the highest levels of photon emission, with
vancomycin or linezolid treatment leading to a reduction in the
bioluminescence signal during the course of infection. Quantifi-
cation of the bacterial burden at day 7 p.i. showed that treatment
with vancomycin resulted in a 100-fold reduction in S. aureus;
however, linezolid had a greater effect, reducing the bacterial
burden by 6 log10 units compared with that in the mock-treated
control group. These results are in line with those of previous
studies showing that vancomycin has relatively weak antibacterial
activity in murine abscess models [11,18]. Quantification of both
cfu and BL signal intensity showed the efficacy of both antibiotics,
and that linezolid was superior to vancomycin in this model;
however, the cfu data revealed a greater difference between the
two antibiotics.
Figure 3. 19F filled volume in the infected thigh muscle at days 3 and 7 post-infection. S. aureus Xen 29 (3.26108) was injected into the
left thigh muscle and the PFC tracer was administered intravenously 48 h post-infection. Mice underwent MRI at 12 h and 120 h after PFC
administration. The number of 19F filled voxels in each infected muscle and the median for each group are shown. Statistically significant differences
between the groups are indicated by asterisks (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0064440.g003
Figure 4. Overall 19F signal in the infected thigh muscle at days 3 and 7 post-infection. S. aureus Xen 29 (3.26108) was injected into the
left thigh muscle and the PFC tracer was administered intravenously 48 h post-infection. Mice underwent MRI at 12 h and 120 h after PFC
administration. The overall 19F signal of all 19F filled voxels in each infected thigh muscle and the median for each group are shown. Statistically
significant differences between the groups are indicated by asterisks (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0064440.g004
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These methods assess bacterial burden either directly (cfu
counting) or indirectly (BLI). Therefore, we tried to determine
whether 19F MRI using PFCs allows the visualization of the
infection process and the in vivo assessment of the activity of
antibiotics in a non-invasive manner. In this regard, 19F MRI with
PFCs cannot directly determine bacterial numbers during the
infection process; rather, it enables the visualization of the host
immune response by labeling phagocytic immune cells [14,17].
Our main goal was to identify a method capable of providing
information about the infection process in vivo using non-invasive
imaging technology.
In a previous study, we showed that intravenous administration
of PFCs as early as 48 h p.i. led to a stable 19F signal at the site of
infection up until at least 9 days p.i. [16]. However, the 19F
accumulation pattern at the site of infection, and the response to
antibiotic therapy, has not been examined to date. In all animals,
including those treated with antibiotics, 19F accumulated at the
rim of the abscess, forming a hollow sphere. These results
indicated that antibiotic therapy did not prevent PFC accumula-
tion at the site of infection, nor did it inhibit visualization of the
abscess area by 19F MRI. Since the three dimensional accumu-
lation pattern did not form a completely closed hollow sphere the
volume of the abscess area could not be measured directly (see S1–
S6). Therefore, we estimated the infection volume indirectly by
measuring the accumulation of PFC-filled voxels around the
infection area. The calculated volume of PFC-filled voxels
correlated qualitatively with treatment efficacy, as indicated by
bioluminescence imaging and cfu data. The second quantifiable
parameter, the overall 19F signal strength in the infected thigh
muscle, also showed the highest value in the mock-treated group
and the lowest in the linezolid group, with an intermediate value in
response to vancomycin (Fig. 4); these results were in agreement
with the results of bioluminescence imaging and cfu determina-
tion. Bioluminescence accumulation and 19F filled volume or
signal intensity identified comparable differences in magnitude
between the treatment groups, whereas cfu determination detected
greater differences. These results suggest that the number of
phagocytic cells in an abscess area correlates with the number of
live S. aureus bacteria within the abscess. A small increase in the 19F
signal was observed between day 3 p.i. (12 h after PFC
administration) and day 7 p.i. in all treatment groups, indicating
that the PFC tracer was transported to the site of infection more
than 12 h post-administration, and was retained there for a long
time.
Overall, both the 19F filled volume and the 19F signal intensity
in the infected thigh muscle correlated with the efficacy of the
tested antibiotics at both time points, with the highest signals
observed in the mock-treated group and the lowest in the linezolid-
treated group. 19F MRI with PFCs is independent of the infecting
pathogen, because the contrast media accumulates at the site of
inflammation after phagocytosis by circulating immune cells and
their subsequent migration [14,15]. Therefore, this method may
be useful for assessing inflammatory responses to new drug
candidates by measuring the number of phagocytic cells at the site
of infection. Furthermore, 19F MRI delivers a more detailed
picture of the state of disease than the classical determination of
bacterial burden because it allows the visualization of the tissue at
the site of infection, pathogen induced changes, and the
quantification of phagocytes. Further studies are necessary to
assess the potential of 19F MRI to detect infection foci of unknown
origin. In medical practice, severe and complicated infections
caused by S. aureus, such as osteomyelitis, are often difficult to
recognize and are associated with high rates of treatment failure.
Therefore, accurate localization of the infection focus could help
determine the most appropriate therapeutic measures. Moreover,
the visualization and assessment of soft tissue abscesses could be a
promising approach to tracking and measuring the efficacy of
antibiotic therapy.
In conclusion, the results of the present study indicate that the
accumulation of PFC emulsions at the site of infection reflects the
immune response to antibacterial therapy, and is therefore a useful
approach to evaluating antibiotics in preclinical infectious disease
models. Visualization of PFC accumulation by 19F MRI might
enable the clinician to differentiate between infected and non-
infected tissues, and is a promising tool for indirectly estimating the
abscess area and the effects of antibiotics.
Materials and Methods
Ethics Statement
The present study was approved by the Committee on the
Ethics of Animal Experiments of the government of Lower
Franconia (55.2-2531.01-06/12) and all experiments were per-
formed in strict accordance with the German animal protection
laws. All animals were kept in cages under standardized lighting
conditions and had access to food and water ad libitum. In vivo
imaging was performed under isoflurane anesthesia, and all efforts
were made to minimize suffering. Animals were sacrificed at the
end of the experiment by CO2 inhalation.
Materials
Vancomycin and linezolid were purchased from Sigma Aldrich
(St. Louis, Mo, USA) and dissolved in sterile 0.9% NaCl solution.
The 19F nanoemulsion core compound was PFC, with a mean
droplet diameter of approximately 145 nm. A 20% (v/v) emulsion
(VS1000H, Celsense, Inc., Pittsburgh, USA) was used for direct
intravenous injection.
Murine Thigh Abscess Model
The murine S. aureus thigh infection model was selected because
of the localized and bulky abscesses generated by this model [19].
A total of 16 female Balb/C mice (18–22 g, Charles-River,
Germany) were used for the study. The animals were anesthetized
with isoflurane (1.5% isoflurane in O2) and 50 mL of bacterial
suspension (3.26108 cfu per infection dose) in 0.9% NaCl was
inoculated into the left thigh muscle. The bacterial suspension was
prepared by overnight incubation of S. aureus Xen 29 (Caliper Life
Sciences, Waltham, MA, USA) in liquid B-medium. The bacteria
were then washed, resuspended in 0.9% NaCl and diluted to a
final concentration of 6.46109 cfu/mL. The infection dose was
controlled by optical density and assessed by plating dilutions on
agar plates.
The mice were then assigned to one of three treatment
groups. The mock-treated group (0.9% NaCl group) received
50 mL of 0.9% NaCl i.p. 2 h p.i, and then every 12 h
thereafter. The antibiotic treatment groups (vancomycin or
linezolid) received the first antibiotic treatment 2 h p.i. and then
every 12 h thereafter. The dosing regimen was 30 mg/kg/d for
vancomycin and 15 mg/kg/d for linezolid. All mice received a
single intravenous dose (100 mL) of PFC contrast media on day
2 p.i. Photon emission was detected by BLI before, at 15 min
p.i., and then every 24 h. The accumulation of 19F at the site of
infection was visualized by MRI at day 3 p.i. (12 h post-PFC
administration) and at day 7 p.i. (5 days post-PFC administra-
tion). The animals were sacrificed after the final MRI on day 7
p.i. by inhalation of pure CO2.
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Magnetic Resonance Imaging
MRI experiments were performed on a 7 Tesla Bruker Biospec
System (Bruker BioSpin GmbH, Reinstetten, Germany) at room
temperature with a double resonant (1H and 19F) home-built
birdcage. The animals were anesthetized (1% isoflurane) and
placed in a home-built container to comply with safety regulations.
1H MRI anatomical imaging was performed by a turbo spin
echo (TSE) sequence (TEeff/TR: 20.4 ms/500 ms; inter-echo
time: 5.1 ms; turbo factor: 4; FOV: 25625625 mm3; matrix:
1006966100; NA: 1).
For 19F-MRI, two acquisition-weighted [20] 3D steady-state
free precession chemical shift imaging (SSFP-CSI) sequences [21]
were performed with the same geometry as that used for the 1H-
TSE scans, but with different pulse phase increments (h: 0u/180u,
pulse shape: hermite; pulse bandwidth: 5400 Hz; TACQ/TR:
10.24 ms/13.1 ms; FOV: 25625616 mm3; spectral points: 512;
acquired resolution/time equivalent: - matrix: 31631620; - NA:
4). The overall protocol took less than 1.5 h. The two acquired
datasets were combined using ‘‘sum-of-squares’’ (SoS) to reduce
the banding artefacts. The 19F spectral line was pixel-wise summed
up and the resulting data were zero-filled to a matrix of
1006100664 pixels.
MR-Quantification
Because of time restrictions for the in vivo experiments, 19F B1
maps, which are mandatory for absolute MR signal quantification,
could not be acquired for every mouse. Therefore, absolute
quantification of the 19F content was not possible. To minimize
this B1-effect and achieve the highest comparability between all
experiments, we used mice of matching size and weight that were
similarly positioned in the rather homogeneous B1-field of a
birdcage coil. Consequently, we used the 19F MR signal intensity,
normalized to the apparent noise amplitude of the measurement
(nsif), as an estimate of the 19F content. The apparent mean noise
amplitude and the variation of the background signal s of the
processed 19F images was thereby determined by fitting the
histogram of the pixel intensities, using a Gaussian noise model as
an approximation. To avoid false positive events, we considered a
voxel as ‘fluorine filled’ if the corresponding 19F signal intensity
was greater than the apparent mean noise amplitude plus 4 s.
This threshold was used for all further examinations.
Bioluminescence Imaging
BLI was performed with an In Vivo Imaging System (IVIS
Lumina II, Caliper Life Sciences, USA). The mice were
anesthetized with 2% isoflurane and imaged using the following
parameters: exposure, 120 s; FStop, 1; excitation, block; emission,
open; FOV, D; height, 1.5 cm. A standardized area of interest was
manually defined at the site of infection, with the same size and
geometry for all mice and all time points. This was necessary to
determine the values for all animals because of the lack of signal
above background noise in some mice, in particular those in the
linezolid group. To overcome this, we defined an area of interest at
the site of infection to determine average radiance values for
comparison between groups. The average radiance values were
then analyzed using Living Image 3.2 software (Caliper Life
Sciences, USA).
Counting the Number of Colony-forming Units
The infected thigh muscles were removed on day 7 p.i. and
homogenized in a tissue homogenizer. The homogenate was then
serially diluted in sterile 0.9% NaCl, and several dilutions were
plated on B agar plates and cultivated overnight. The number of
colonies on the plates was then counted.
Statistical Analysis
Data analysis was performed using GraphPad Prism 5.0
software (GraphPad, San Diego, USA) and groups were compared
using the Mann-Whitney U test (*P,0.05, **P,0.01). The results
are expressed as the median value of all measurements and groups
(with the exception of Fig. 1, in which the mean BL signal 6 SEM
is shown).
Supporting Information
Video S1 Representative 3D visualization of 19F chemical shift
imaging steady-state free precession overlays on 1H- turbo spin
echo scans at day 3 post-infection in mock-treated mice. S. aureus
Xen 29 was injected into the left thigh muscle of the mice and a
perfluorocarbon (PFC) emulsion was administered intravenously
48 h later. MRI was performed 24 h after PFC administration.
The video was generated using MeVislab (Fraunhofer Mevis,
Bremen, Germany).
(AVI)
Video S2 Representative 3D visualization of 19F chemical shift
imaging steady-state free precession overlays on 1H- turbo spin
echo scans at day 7 post-infection in mock-treated mice. S. aureus
Xen 29 was injected into the left thigh muscle of the mice and a
perfluorocarbon emulsion was administered intravenously 48 h
later. MRI was performed on day 7 p.i. The video was generated
using MeVislab (Fraunhofer Mevis, Bremen, Germany).
(AVI)
Video S3 Representative 3D visualization of 19F chemical shift
imaging steady-state free precession overlays on 1H- turbo spin
echo scans at day 3 post-infection during Vancomycin treatment.
S. aureus Xen 29 was injected into the left thigh muscle of the mice
and a perfluorocarbon (PFC) emulsion was administered intrave-
nously 48 h later. Vancomycin (30 mg/kg/d) was administered
intraperitoneally 2 h post-infection, and then every 12 h thereaf-
ter. MRI was performed 24 h after PFC administration. The video
was generated using MeVislab (Fraunhofer Mevis, Bremen,
Germany).
(AVI)
Video S4 Representative 3D visualization of 19F chemical shift
imaging steady-state free precession overlays on 1H- turbo spin
echo scans at day 7 post-infection during Vancomycin treatment.
S. aureus Xen 29 was injected into the left thigh muscle of the mice
and a perfluorocarbon emulsion was administered intravenously
48 h later. Vancomycin (30 mg/kg/d) was administered intraper-
itoneally 2 h post-infection and then every 12 h thereafter. MRI
was performed on day 7 post-infection. The video was generated
using MeVislab (Fraunhofer Mevis, Bremen, Germany).
(AVI)
Video S5 Representative 3D visualization of 19F chemical shift
imaging steady-state free precession overlays on 1H- turbo spin
echo scans at day 3 post infection during Linezolid treatment. S.
aureus Xen 29 was injected into the left thigh muscle of the mice
and a perfluorocarbon (PFC) emulsion was administered intrave-
nously 48 h later. Linezolid (15 mg/kg/d) was administered
intraperitoneally 2 h post-infection and then every 12 h thereafter.
MRI was performed 24 h after PFC administration. The video
was generated using MeVislab (Fraunhofer Mevis, Bremen,
Germany).
(AVI)
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Video S6 Representative 3D visualization of 19F chemical shift
imaging steady-state free precession overlays on 1H- turbo spin
echo scans at day 7 post infection during Linezolid treatment. S.
aureus Xen 29 was injected into the left thigh muscle of the mice
and a perfluorocarbon emulsion was administered intravenously
48 h later. Linezolid (15 mg/kg/d) was administered intraperito-
neally 2 h post-infection and then every 12 h thereafter. MRI was
performed at day 7 post-infection. The video was generated using
MeVislab (Fraunhofer Mevis, Bremen, Germany).
(AVI)
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